Sales effectiveness focus with disciplined cost management results in improved revenues and margins while reducing debt Revenue returns to pre-Covid19 levels on strong CRO/pharma sales Operating margin increased year-over-year on GAAP and an adjusted basis New debt facility significantly reduces
HOLLISTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2020 before the market opens on March 10, 2021, and will hold a conference call to discuss the results on March 10, 2021 at 8:00 a.m.
HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference.
Disciplined cost management, cash conservation actions drive increased year-over-year operating income and reduced net debt Operating margin up year-over-year on GAAP and adjusted basis Revenue improved sequentially with solid CRO/pharma demand and academic labs reopening Generated positive
HOLLISTON, MA. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2020 before the market opens on November 5, 2020 , and will hold a conference call to discuss the results on November 5, 2020 at 8:00
HOLLISTON, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelling Values 2020 Webinar on September 17, 2020 at 2:15 p.m. ET.
Accelerated cost reduction, cash conservation actions drive increased operating income, reduced net debt Operating Income up sequentially and year-over-year on both GAAP and adjusted basis Cost reduction programs offset expected declines in Academic markets Net Debt reduced by $2.2 million in Q2
HOLLISTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August 5, 2020, and will hold a conference call to discuss the results on August 5, 2020 at 8:00 a.m.
Provides Update on Performance Against Previously Announced Strategic Plan HOLLISTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Jim Green, Chairman, President & Chief Executive Officer of Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today issued a letter to
